| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $1,877,772 | 32 | 100 |
Sells | $0 | 0 | 0 |
| STERTZER SIMON H | director | 3 | $847,998 | 0 | $0 | $847,998 |
| Blank Andrew Scott | director | 3 | $759,999 | 0 | $0 | $759,999 |
| Altman Peter | President and CEO | 22 | $184,778 | 0 | $0 | $184,778 |
| McClung David | Chief Financial Officer | 2 | $34,999 | 0 | $0 | $34,999 |
| Facteau Bill | director | 1 | $24,999 | 0 | $0 | $24,999 |
| KRASNO RICHARD M | director | 1 | $24,999 | 0 | $0 | $24,999 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Over the last 12 months, insiders at BioCardia, Inc. have bought $1.88M and sold $0 worth of BioCardia, Inc. stock.
On average, over the past 5 years, insiders at BioCardia, Inc. have bought $604,271 and sold $31,164 worth of stock each year.
Highest buying activity among insiders over the last 12 months: STERTZER SIMON H (director) — $847,998. Blank Andrew Scott (director) — $759,999. Altman Peter (President and CEO) — $184,778.
The last purchase of 5,000 shares for transaction amount of $5,650 was made by Altman Peter (President and CEO) on 2026‑02‑04.
| 2026-02-04 | Altman Peter | President and CEO | 5,000 0.0894% | $1.13 | $5,650 | +9.17% | ||
| 2026-01-21 | Altman Peter | President and CEO | 300 0.0054% | $1.34 | $402 | -3.91% | ||
| 2026-01-20 | Altman Peter | President and CEO | 600 0.0105% | $1.32 | $792 | -5.00% | ||
| 2025-12-17 | Altman Peter | President and CEO | 900 0.0159% | $1.30 | $1,170 | 0.00% | ||
| 2025-12-16 | Altman Peter | President and CEO | 200 0.0037% | $1.37 | $274 | -0.78% | ||
| 2025-09-19 | Blank Andrew Scott | director | 288,000 5.3496% | $1.25 | $360,000 | +12.93% | ||
| 2025-09-19 | STERTZER SIMON H | director | 398,400 7.4003% | $1.25 | $498,000 | +12.93% | ||
| 2025-09-19 | Altman Peter | President and CEO | 48,000 0.8916% | $1.25 | $60,000 | +12.93% | ||
| 2025-08-13 | Altman Peter | President and CEO | 100 0.0017% | $1.83 | $183 | -27.96% | ||
| 2025-08-12 | Altman Peter | President and CEO | 400 0.0074% | $1.75 | $700 | -22.70% | ||
| 2025-08-11 | Altman Peter | President and CEO | 1,700 0.0318% | $1.76 | $2,989 | -19.64% | ||
| 2025-06-30 | Blank Andrew Scott | director | 72,289 1.4856% | $2.08 | $150,000 | -28.21% | ||
| 2025-06-30 | STERTZER SIMON H | director | 72,289 1.4856% | $2.08 | $150,000 | -28.21% | ||
| 2025-06-30 | Altman Peter | President and CEO | 24,096 0.4952% | $2.08 | $49,999 | -28.21% | ||
| 2025-06-30 | McClung David | Chief Financial Officer | 4,819 0.099% | $2.08 | $9,999 | -28.21% | ||
| 2025-05-30 | Altman Peter | President and CEO | 100 0.002% | $2.21 | $221 | -34.26% | ||
| 2025-05-22 | Altman Peter | President and CEO | 700 0.0134% | $1.89 | $1,323 | -25.26% | ||
| 2025-05-20 | Altman Peter | President and CEO | 1,600 0.0328% | $2.08 | $3,328 | -27.04% | ||
| 2025-05-16 | Altman Peter | President and CEO | 300 0.0058% | $2.43 | $730 | -41.39% | ||
| 2025-05-14 | Altman Peter | President and CEO | 100 0.0021% | $2.99 | $299 | -48.38% |
| Blank Andrew Scott | director | 634023 10.9337% | $748,147.14 | 4 | 0 | +44.98% |
| STERTZER SIMON H | director | 591054 10.1927% | $697,443.72 | 24 | 0 | <0.0001% |
| Altman Peter | President and CEO | 273866 4.7228% | $323,161.88 | 90 | 0 | <0.0001% |
| McClung David | Chief Financial Officer | 47950 0.8269% | $56,581.00 | 8 | 0 | |
| KRASNO RICHARD M | director | 16268 0.2805% | $19,196.24 | 1 | 0 | |
| Facteau Bill | director | 13123 0.2263% | $15,485.14 | 1 | 0 | |
| Brooks Andrew A | CEO | 63560031 1096.0863% | $75M | 11 | 0 | |
| BROOKS JONATHAN | director, 10 percent owner | 32045292 552.6178% | $37.81M | 1 | 2 | |
| FROST PHILLIP MD ET AL | 10 percent owner | 1896025 32.6968% | $2.24M | 19 | 2 | |
| Allen Jim L. | director | 668200 11.523% | $788,476.00 | 1 | 0 | +44.98% |
| Morgan Thomas H. | director | 40419 0.697% | $47,694.42 | 3 | 8 | |
| GILLIS EDWARD M | Senior Vice President, Devices | 8968 0.1547% | $10,582.24 | 0 | 1 | |
| GERAGHTY KENNETH G | director, 10 percent owner | 6221 0.1073% | $7,340.78 | 2 | 0 | |
| GOTTLIEB CORREY J | director | 3333 0.0575% | $3,932.94 | 1 | 0 | |
| MERCORELLA ANTHONY J | director | 333 0.0057% | $392.94 | 1 | 0 | |
| GERSTENBLATT RANDY | director | 66 0.0011% | $77.88 | 1 | 0 | |
| ISRAEL ROY | Chairman,CEO & President | 0 0% | $0 | 0 | 3 | |
| GIULIANI RHEAUME PATRICIA A | VP, CFO & Treasurer | 0 0% | $0 | 0 | 1 | |
| SPECHT WILLEM F | director | 0 0% | $0 | 0 | 1 | |
| Good Kenneth W | director, 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Richards Ronald N. | director | 0 0% | $0 | 1 | 1 | |
| Kvitnitsky Mikhail | 10 percent owner | 0 0% | $0 | 0 | 1 |
$13,664,154 | 40 | -70.35% | $6.22M | |
$1,029,337 | 36 | -28.38% | $7.83M | |
$29,635,355 | 27 | 9.05% | $5.68M | |
$63,749,694 | 24 | -12.24% | $8.06M | |
$37,200,153 | 21 | -47.67% | $8.25M | |
BioCardia, Inc. (BCDA) | $1,039,491 | 21 | -11.76% | $6.84M |
$742,412 | 14 | -50.36% | $5.93M | |
$405,510 | 11 | -46.23% | $6.41M | |
$188,726 | 11 | -28.87% | $8.17M | |
$684,058 | 11 | -57.59% | $5.1M | |
$120,379 | 10 | -24.48% | $7.28M | |
$211,895 | 8 | -39.70% | $7.03M | |
$8,971,546 | 8 | 6.18% | $5.37M | |
$159,974 | 7 | -18.60% | $6.45M | |
$1,184,658 | 4 | -22.17% | $7.38M | |
$76,299 | 4 | 11.60% | $4.98M | |
$1,057,000 | 3 | 5.27% | $6.54M | |
$28,395 | 3 | 3.48% | $7.97M | |
$31,190 | 2 | -14.18% | $6.9M |
| Increased Positions | 12 | +80% | 249,071 | +58.32% |
| Decreased Positions | 5 | -33.33% | 26,549 | -6.22% |
| New Positions | 4 | New | 174,386 | New |
| Sold Out Positions | 2 | Sold Out | 20,170 | Sold Out |
| Total Postitions | 22 | +46.67% | 649,615 | +52.1% |
| Cm Management, Llc | $165.00 | 1.18% | 130,000 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $123.00 | 0.88% | 96,498 | +83,614 | +648.98% | 2025-09-30 |
| Susquehanna International Group, Llp | $49.00 | 0.35% | 38,808 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $49.00 | 0.35% | 38,740 | +1,277 | +3.41% | 2025-09-30 |
| Brown Advisory Inc | $45.00 | 0.32% | 35,538 | 0 | 0% | 2025-09-30 |
| Two Sigma Securities, Llc | $25.00 | 0.18% | 19,337 | +19,337 | New | 2025-09-30 |
| Commonwealth Equity Services, Llc | $23.00 | 0.17% | 18,283 | +200 | +1.11% | 2025-09-30 |
| Wealth Enhancement Advisory Services, Llc | $22.00 | 0.16% | 17,000 | +17,000 | New | 2025-09-30 |
| Xtx Topco Ltd | $21.00 | 0.15% | 16,177 | +16,177 | New | 2025-09-30 |
| Ubs Group Ag | $14.00 | 0.1% | 10,740 | +6,561 | +157% | 2025-09-30 |